Biomarkers such as phosphorylated tau (p-tau) in Alzheimer’s and neurofilament light chain (NfL) in MS allow for real-time monitoring that can guide therapeutic adjustments, track treatment efficacy, and offer an ongoing view of disease progression. This evidence concerns the gene MAPT and myeloid sarcoma.